The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany

Abstract Background We analysed the impact of clinical study design for oncological pharmaceuticals on the subsequent price negotiations after early benefit assessment between pharmaceutical companies and the German National Association of Statutory Health Insurance Funds. The analysis was conducted...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: C. M. Dintsios, I. Beinhauer
Médium: Artigo
Jazyk:Inglês
Vydáno: BMC 2020-03-01
Edice:Health Economics Review
Témata:
Study design
Negotiated prices
Oncological drugs
Pharmaceutical companies
Payers
German statutory health insurance
On-line přístup:http://link.springer.com/article/10.1186/s13561-020-00263-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky